Clinical trials: Essential Hypertension.
Essential Hypertension
Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine
This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.
- Trial name
- AWESOME (NCT01113047)
- Testing
- Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ
- Where
- Germany
- Volunteers
- 347 people
- Sponsor
- Novartis
Primary Hypertension
A Study of LY2623091 in Participants With High Blood Pressure
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.
- Trial name
- NCT02194465
- Testing
- LY2623091, Tadalafil, Spironolactone
- Where
- 43 sites in United States, Canada and 1 more
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Essential Hypertension
Clinical Efficacy and Safety Evaluation of Irbesartan High and Amlodipine Combined Therapy in Essential Hypertension Patients
The purpose of this study is to evaluate efficacy and safety of Irbesartan and Amlodipine combined therapy in patients with essential hypertension inadequately controlled on Irbesartan monotherapy
- Trial name
- NCT05475665
- Testing
- Irbesartan/Amlodipine, Irbesartan
- Where
- South Korea
- Volunteers
- 157 people
- Sponsor
- Handok Inc.
Cardiovascular Diseases, Heart Diseases
Molecular Epidemiology of Essential Hypertension
To localize individual genes, called blood pressure quantitative trait genes [BPQTGs], which influence blood pressure levels in the population-at- large, and to determine if these genes are able to predict the occurrence of…
- Conditions
- Cardiovascular Diseases, Heart Diseases, Coronary Disease, Hypertension
- Trial name
- NCT00005377
- Volunteers
- 573 people, healthy volunteers welcome
- Sponsor
- The University of Texas Health Science Center, Houston
Essential Hypertension
Uric Acid in Essential Hypertension in Children
The study is a randomized, double-blinded, placebo controlled, crossover trial of allopurinol for the treatment of children with newly diagnosed essential hypertension.
- Trial name
- NCT00288184
- Testing
- Allopurinol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Hypertension
High Dose BAYA1040 CR: a Long Term Extension Study
This is a clinical study evaluating the safety and efficacy of long term administration of oral BAYA1040 CR 80 mg/day (40 mg twice daily) in patients with essential hypertension for whom the test drug is tolerable during the 8…
- Trial name
- NCT01355367
- Testing
- Nifedipine (Adalat, BAYA1040)
- Where
- 22 sites in Japan
- Volunteers
- 120 people
- Sponsor
- Bayer
Hypertension
Sitogilun Malate Plus Amlodipine in Patients With Hypertension and Risk of Early Kidney Damage
This is a multicenter, randomized, double-blind, parallel-controlled Phase IV clinical trial designed to evaluate the efficacy and safety of sitogilun malate tablets in combination with amlodipine besylate tablets in patients…
- Trial name
- SABER (NCT07876544)
- Testing
- Sitogilun Malate, Allisartan Isoproxil, Amlodipine besylate
- Where
- China
- Volunteers
- 456 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Metabolic Syndrome, Cardiovascular Risk Factor
Plant-based Nutrition for Patients With Cardiovascular Risk Factors
Plant-based nutrition may have positive effects on chronic diseases such as cardiovascular or metabolic disorders. This study investigates the effects of a 8 week plant-based diet for patients with metabolic syndrom and…
- Conditions
- Metabolic Syndrome, Cardiovascular Risk Factor, Overweight and Obesity, Hypertension,Essential
- Trial name
- CardioVeg (NCT03901183)
- Testing
- Plant-based Diet
- Where
- Germany
- Volunteers
- 70 people
- Sponsor
- Charite University, Berlin, Germany
Essential Hypertension
Monitoring the Effectiveness and Safety of Antihypertensive Therapy With a Fixed-Dose Combination of Perindopril and Amlodipine in Patients With Uncontrolled Essential Hypertension
The aim of this observational study is to monitor the effectiveness of therapy, adherence and safety of a fixed combination of perindopril + amlodipine in patients with essential hypertension.
- Trial name
- NCT07876895
- Testing
- fixed combination of perindopril + amlodipine
- Where
- Bosnia and Herzegovina
- Volunteers
- 600 people
- Sponsor
- Bosnalijek D.D
Hypertension
Research Study To Test Carvedilol CR + Lisinopril Versus Lisinopril + Placebo In Patients With High Blood Pressure
Randomized, double-blind, parallel group, multicenter study of subjects with Stage 1 or 2 essential hypertension who are not at target blood pressure (<140/90mmHg) at Baseline.
- Trial name
- NCT00624065
- Testing
- carvedilol controlled release/lisinopril
- Where
- 76 sites in United States
- Volunteers
- 348 people
- Sponsor
- GlaxoSmithKline
Hypertension, Blood Pressure
Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE-HTN-II)
This randomized, blinded, sham-control trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension.
- Conditions
- Hypertension, Blood Pressure, Cardiovascular Diseases
- Trial name
- NCT06018493
- Testing
- focused power ultrasound mediate inferior perirenal adipose tissue modification
- Where
- 4 sites in China
- Volunteers
- 79 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Hypertension
Azilsartan Medoxomil (TAK-491) Compared to Placebo in Korean Adults With Hypertension
The purpose of this study is to compare the antihypertensive effect of azilsartan medoxomil versus placebo in Korean adults with essential hypertension.
- Trial name
- NCT02203916
- Testing
- Azilsartan medoxomil
- Where
- 15 sites in South Korea
- Volunteers
- 328 people
- Sponsor
- Takeda
Essential Hypertension
Assess Sacubitril/Allisartan and Amlodipine in Patients With Essential Hypertension Uncontrolled With Sacubitril/Allisartan
The main objective of the study will be to assess the efficacy and safety of Sacubitril/Allisartan (240mg) and Amlodipine (5mg) in patients with essential hypertension uncontrolled after 4-week treatment with…
- Trial name
- NCT07704697
- Testing
- Experimental: Sacubitril/Allisartan and Amlodipine Group, Active Comparator: Sacubitril/Allisartan Group
- Where
- China
- Volunteers
- 346 people
- Sponsor
- Shenzhen Salubris Pharmaceuticals Co., Ltd.
Hypertension
Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension
Assessing efficacy, safety and pharmacokinetics in patients with mild to moderate essential hypertension
- Trial name
- NCT00344110
- Testing
- Aliskiren
- Where
- Japan
- Volunteers
- 768 people
- Sponsor
- Novartis
Hypertension
Long Term Safety of Aliskiren Alone or With the Optional Addition of Hydrochlorothiazide in Patients With Essential Hypertension
Assess the long-term safety and tolerability of aliskiren, with the optional addition of HCTZ, in patients with essential hypertension, to ensure long term blood pressure control and protect against end organ damage.
- Trial name
- NCT00219037
- Testing
- aliskiren
- Where
- Germany
- Volunteers
- 1,955 people
- Sponsor
- Novartis
Atrial Fibrillation, Hypertension,Essential
Left Atrial Enlargement: A Crucial Indicator for Identifying Atrial Fibrillation in Patients With Hypertension
Based on the data of inpatients with hypertension and a cross-sectional study with a large sample size, this study aims to find the early warning value of the left anteroposterior atrial diameter for the possible occurrence of…
- Conditions
- Atrial Fibrillation, Hypertension,Essential, Left Atrial Dilatation
- Trial name
- NCT06359873
- Testing
- CHA2DS2-VASc score, C2HEST score, and left atrial diameter (LAD)
- Where
- China
- Volunteers
- 58,427 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
Essential Hypertension, Hypercholesterolemia
A Study to Evaluate the Efficacy of Valsartan/Simvastatin Combinations in Patients With Both Essential Hypertension and Hypercholesterolemia
The purpose of this study is to provide data on the dose response of simvastatin in lowering LDL-C when it is co-administered with valsartan in patients with both essential hypertension and hypercholesterolemia.
- Trial name
- NCT00254475
- Testing
- simvastatin, valsartan
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 871 people
- Sponsor
- Novartis
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Hypertension
Efficacy and Safety of LCZ696A in Patients With Essential Hypertension
This study was a dose-ranging efficiacy study in patients with essential hypertension to assess the blood pressure lowering effect, and safety of LCZ696 compared to valsartan and placebo.
- Trial name
- NCT00549770
- Testing
- LCZ696, Valsartan, AHU377
- Where
- 182 sites in United States, Argentina and 16 more
- Volunteers
- 1,334 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension, Postmenopause
Effect of Angeliq on Blood Pressure (BP) in Postmenopausal Hypertensive Women
The objective of the study is to evaluate the effects of Angeliq on BP over a period of 8 weeks in postmenopausal women who may benefit from hormone replacement therapy (HRT) for the relief of vasomotor symptoms and who have…
- Trial name
- NCT00102141
- Testing
- Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)
- Volunteers
- 750 people
- Sponsor
- Bayer